HomeBUSINESS
BUSINESS

Opdivo’s Half-Year Sales Sag as 50% Price Cut Takes Toll: Ono
(Nov.7.2017)

Ono President Gyo Sagara
Ono Pharmaceutical saw sales of its immuno-oncology star Opdivo (nivolumab) slide over 20% in April-September as its expanding indications, which now include renal cell carcinoma (RCC) and head and neck cancer, failed to offset a major blow from a 50% price slash in February ...
(LOG IN FOR FULL STORY)

News Calendar